Journal
Investigational new drugs
Publication Date
12-1-2023
Volume
41
Issue
6
First Page
851
Last Page
860
Document Type
Open Access Publication
DOI
10.1007/s10637-023-01395-y
Rights and Permissions
Wang-Gillam, A., Schelman, W., Ukrainskyj, S. et al. Phase 1/1b open-label, dose-escalation study of fruquintinib in patients with advanced solid tumors in the United States. Invest New Drugs 41, 851–860 (2023). https://doi.org/10.1007/s10637-023-01395-y This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
Recommended Citation
Wang-Gillam, Andrea; Schelman, William; Ukrainskyj, Stacey; Chien, Caly; Gonzalez, Martha; Yang, Zhao; Kania, Marek; and Yeckes-Rodin, Heather, "Phase 1/1b open-label, dose-escalation study of fruquintinib in patients with advanced solid tumors in the United States." Investigational new drugs. 41, 6. 851 - 860. (2023).
https://digitalcommons.wustl.edu/oa_4/3492
Department
ICTS (Institute of Clinical and Translational Sciences)
Additional Links
Supplemental material is available for this article at publisher site.
